ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer

Small‐cell lung cancer (SCLC) is the most lethal type of lung cancer. Specifically, MYC‐driven non‐neuroendocrine SCLC is particularly resistant to standard therapies. Lurbinectedin was recently approved for the treatment of relapsed SCLC, but combinatorial approaches are needed to increase the dept...

Descripción completa

Detalles Bibliográficos
Autores principales: Schultz, Christopher W, Zhang, Yang, Elmeskini, Rajaa, Zimmermann, Astrid, Fu, Haiqing, Murai, Yasuhisa, Wangsa, Darawalee, Kumar, Suresh, Takahashi, Nobuyuki, Atkinson, Devon, Saha, Liton Kumar, Lee, Chien‐Fei, Elenbaas, Brian, Desai, Parth, Sebastian, Robin, Sharma, Ajit Kumar, Abel, Melissa, Schroeder, Brett, Krishnamurthy, Manan, Kumar, Rajesh, Roper, Nitin, Aladjem, Mirit, Zenke, Frank T, Ohler, Zoe Weaver, Pommier, Yves, Thomas, Anish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405061/
https://www.ncbi.nlm.nih.gov/pubmed/37491889
http://dx.doi.org/10.15252/emmm.202217313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405061/
https://www.ncbi.nlm.nih.gov/pubmed/37491889
http://dx.doi.org/10.15252/emmm.202217313

Ejemplares similares